AbCellera Biologics Inc (ABCL)
4.125
-0.06
(-1.55%)
USD |
NASDAQ |
Apr 16, 10:56
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.208B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -43.22% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 31.37 |
| Price to Book Value | 1.048 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program. |
| URL | https://www.abcellera.com |
| Investor Relations URL | https://investors.abcellera.com/ |
| HQ State/Province | British Columbia |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 03, 2024 (est.) |
| Last Earnings Release | Feb. 20, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program. |
| URL | https://www.abcellera.com |
| Investor Relations URL | https://investors.abcellera.com/ |
| HQ State/Province | British Columbia |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 03, 2024 (est.) |
| Last Earnings Release | Feb. 20, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |